Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872‐91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐16.

Article  CAS  PubMed  Google Scholar 

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11‐21.

Article  CAS  PubMed  Google Scholar 

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.

Article  CAS  PubMed  Google Scholar 

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065‐123.

Article  PubMed  Google Scholar 

Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, et al. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging 2018;11:234‐42.

Article  PubMed  Google Scholar 

Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT. J Nucl Med 2021;62:716‐22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM, et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021;28:1835‐45.

Article  PubMed  Google Scholar 

Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA, et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2022;29:2679‐90.

Article  PubMed  Google Scholar 

Watanabe S, Nakajima K, Wakabayashi H, Yoneyama H, Yoshida S, Komatsu J, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2022;29:3102‐10.

Article  PubMed  Google Scholar 

Ogasawara K, Shiraishi S, Tsuda N, Sakamoto F, Oda S, Takashio S, et al. Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis. Jpn J Radiol 2022;40:508‐17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avalon JC, Fuqua J, Deskins S, Miller T, Conte J, Martin D, et al. Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J Nucl Cardiol 2023;30:127‐39.

Article  PubMed  Google Scholar 

Maeda-Ogata S, Tahara N, Tahara A, Bekki M, Honda A, Sugiyama Y, et al. Treatment response to Tafamidis quantitatively assessed by serial bone scintigraphy in transthyretin amyloid cardiomyopathy. J Nucl Cardiol 2023;30:403‐4.

Article  PubMed  Google Scholar 

Sperry BW, Orme NM, Case JA, McGhie AI, Bateman TM. Complete resolution of technetium pyrophosphate uptake after treatment of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2023;16:e014954.

Article  PubMed  Google Scholar 

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, et al. Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid 2018;25:203‐10.

Article  CAS  PubMed  Google Scholar 

Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: a novel imaging biomarker. JACC Cardiovasc Imaging 2020;13:1353‐63.

Article  PubMed  PubMed Central  Google Scholar 

Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 2021;14:189‐99.

Article  PubMed  Google Scholar 

Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019-30.

Papathanasiou M, Kessler L, Bengel FM, Jakstaite AM, Kersting D, Varasteh Z, et al. Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis. J Nucl Med 2023;64:1083‐6.

Article  PubMed  Google Scholar 

Wollenweber T, Rettl R, Kretschmer-Chott E, Rasul S, Kulterer OC, Kluge K, et al. Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT/CT and semiquantitative planar parameters. J Nucl Cardiol. 2022:1-9.

Ramsay SC, Lindsay K, Fong W, Patford S, Younger J, Atherton J. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging. 2018;2:17.

Article  PubMed  Google Scholar 

Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med 2014;55:884‐90.

Article  CAS  PubMed  Google Scholar 

Kessler L, Fragoso Costa P, Kersting D, Jentzen W, Weber M, Ludike P, et al. Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis. J Nucl Cardiol 2023;30:101‐11.

Article  PubMed  Google Scholar 

Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol 2020;27:1456‐63.

Article  PubMed  Google Scholar 

Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014‐20.

Article  PubMed  Google Scholar 

Sengelov M, Jorgensen PG, Jensen JS, Bruun NE, Olsen FJ, Fritz-Hansen T, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging 2015;8:1351‐9.

Article  PubMed  Google Scholar 

Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015;132:402‐14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 2019;12:810‐9.

Article  PubMed  Google Scholar 

Vranian MN, Sperry BW, Hanna M, Hachamovitch R, Ikram A, Brunken RC, et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol 2018;25:1247‐56.

Article  PubMed  Google Scholar 

Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880‐9.

Article  PubMed  Google Scholar 

Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol 2018;25:181‐90.

Article  PubMed  Google Scholar 

Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, et al. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99m-pyrophosphate scintigraphy. J Nucl Cardiol 2017;24:1094‐7.

Article  PubMed  Google Scholar 

Sperry BW, Burgett E, Bybee KA, McGhie AI, O’Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol 2020;27:1802‐7.

Article  PubMed  Google Scholar 

Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249.

Article  PubMed  PubMed Central  Google Scholar 

Regis C, Harel F, Martineau P, Gregoire J, Abikhzer G, Juneau D, et al. Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: comparison of quantitative and semi-quantitative approaches. J Nucl Cardiol 2020;27:1808‐15.

Article  PubMed  Google Scholar 

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐68.

Article  PubMed  PubMed Central  Google Scholar 

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2021;28:1769‐74.

Article  PubMed  Google Scholar 

Castano A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2016;23:1355‐63.

Article  PubMed